A Phase 4 interventional study of Cyclosporine A and Tacrolimus in Liver Transplant, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether cyclosporine A (in a micro emulsion formulation) monitored by sample taken 2 hour after oral dose (C-2h) will show equivalent or superior efficacy compared to tacrolimus monitored by pre-dose blood concentration (C-0h). In addition this study will assess the safety and tolerability of a cyclosporine A regimen based on C-2h monitoring in comparison to the standard tacrolimus regimen.
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined exclusion criteria applied
Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; \> 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.
Drug: Cyclosporine A · Drug: Basiliximab · Drug: Methylprednisolone · Drug: Prednisone
Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; \> 6 months: range of 5-10 ng/ml is recommended.
Drug: Tacrolimus · Drug: Basiliximab · Drug: Methylprednisolone · Drug: Prednisone
Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation.
A BPAR is defined when the investigator had a suspicion of an acute rejection, where the final clinical diagnosis confirmed the occurrence of an acute rejection, where a biopsy was performed that confirmed the presence of an acute rejection, and where anti-rejection treatment intervention was initiated. The efficacy measured the first rejections (clinically and biopsy proven rejections) at 3 months.
Time frame: Month 3
| Milestone | Cyclosporine A | Tacrolimus |
|---|---|---|
| Started | 85 | 86 |
| Completed | 84 | 85 |
| Not completed | 1 | 1 |
| Withdrew: Administrative problems: | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
A BPAR is defined when the investigator had a suspicion of an acute rejection, where the final clinical diagnosis confirmed the occurrence of an acute rejection, where a biopsy was performed that confirmed the presence of an acute rejection, and where anti-rejection treatment intervention was initiated. The efficacy measured the first rejections (clinically and biopsy proven rejections) at 3 months.
| Percentage of Participants | Cyclosporine A | Tacrolimus |
|---|---|---|
| Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation. | 33.3 | 32.9 |
Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tacrolimus | — | 42/86 (48.8%) | 84/86 (97.7%) |
| Cyclosporine A | — | 33/85 (38.8%) | 85/85 (100%) |
| Event | Tacrolimus | Cyclosporine A |
|---|---|---|
| PyrexiaGeneral disorders | 11/86 | 4/85 |
| Biliary anastomosis complicationInjury, poisoning and procedural complications | 3/86 | 3/85 |
| VomitingGastrointestinal disorders | 3/86 | 0/85 |
| CholangitisHepatobiliary disorders | 3/86 | 2/85 |
| AscitesGastrointestinal disorders | 0/86 | 2/85 |
| DiarrhoeaGastrointestinal disorders | 0/86 | 2/85 |
| CholestasisHepatobiliary disorders | 0/86 | 2/85 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/86 | 2/85 |
| Back painMusculoskeletal and connective tissue disorders | 2/86 | 2/85 |
| Nephropathy toxicRenal and urinary disorders | 0/86 | 2/85 |
| Event | Tacrolimus | Cyclosporine A |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 26/86 | 54/85 |
| InsomniaPsychiatric disorders | 30/86 | 46/85 |
| OedemaGeneral disorders | 41/86 | 37/85 |
| NauseaGastrointestinal disorders | 40/86 | 39/85 |
| Enterococcal infectionInfections and infestations | 28/86 | 37/85 |
| AscitesGastrointestinal disorders | 29/86 | 35/85 |
| Staphylococcal infectionInfections and infestations | 34/86 | 33/85 |
| PyrexiaGeneral disorders | 25/86 | 33/85 |
| Procedural painInjury, poisoning and procedural complications | 22/86 | 33/85 |
| HypertensionVascular disorders | 33/86 | 21/85 |
| Age Continuous(Years) | Cyclosporine A | Tacrolimus | Total |
|---|---|---|---|
| Mean | 48.1 ± 12.069 | 49.9 ± 9.886 | 48.98 ± 11.029 |
| Sex: Female, Male(Participants) | Cyclosporine A | Tacrolimus | Total |
|---|---|---|---|
| Female | 31 | 30 | 61 |
| Male | 53 | 55 | 108 |
The record gives a start of Dec 2002, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine